<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-71557" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Somatostatinoma</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Elangovan</surname>
            <given-names>Abbinaya</given-names>
          </name>
          <aff>Case Western Reserve / MetroHealth</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Mathias</surname>
            <given-names>Priyanka M.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Zulfiqar</surname>
            <given-names>Hassam</given-names>
          </name>
          <aff>Hamad Medical Corporation, Doha, Qatar</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Abbinaya Elangovan declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Priyanka Mathias declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Hassam Zulfiqar declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>25</day>
          <month>6</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-71557.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p>Somatostatinoma is a rare neuroendocrine tumor (NET) with an incidence of 1 in 40 million individuals and accounts for less than 5% of pancreatic NETs (pNETs). This activity outlines the evaluation and treatment of somatostatinoma and highlights the role of the interprofessional team in managing patients with this condition.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the pathophysiology of somatostatinoma.</p></list-item><list-item><p>Outline the typical presentation and common exam findings of a patient with somatostatinoma.</p></list-item><list-item><p>Summarize the typical imaging findings associated with somatostatinoma.</p></list-item><list-item><p>Explain the importance of care coordination among the interprofessional team to decide management based on prognosis.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=71557&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=71557">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-71557.s2" sec-type="pubmed-excerpt">
        <title>Introduction</title>
        <p>Somatostatinoma is a rare neuroendocrine tumor (NET) with an incidence of 1 in 40 million individuals<xref ref-type="bibr" rid="article-71557.r1">[1]</xref> and accounts for less than 5% of pancreatic NETs (pNETs).<xref ref-type="bibr" rid="article-71557.r2">[2]</xref>&#x000a0;The tumor was first described in 1977 in a 46-year-old woman in the head of the pancreas.<xref ref-type="bibr" rid="article-71557.r3">[3]</xref>&#x000a0;The tumor originates from the delta cells of the pancreas and predominantly contains somatostatin with trace quantities of other pancreatic hormones such as insulin, glucagon, gastrin, and vasoactive intestinal polypeptide.&#x000a0;It remains&#x000a0;localized to the pancreas in 56 to 70% of the cases, out of which 36% occur in the head, 14% in the pancreatic body, and 32% in the tail.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref>&#x000a0;Other common sites include duodenum (19%), ampulla of Vater (3%), and small bowel (3%).<xref ref-type="bibr" rid="article-71557.r5">[5]</xref>&#x000a0;Reports exist of rare instances of extra-gastrointestinal primaries in the lungs, kidneys, and thyroid.<xref ref-type="bibr" rid="article-71557.r6">[6]</xref></p>
      </sec>
      <sec id="article-71557.s3" sec-type="Etiology">
        <title>Etiology</title>
        <p>Somatostatinoma&#x000a0;can be sporadic or may occur in association with neurocutaneous syndromes such as multiple endocrine neoplasia type 1 (the commonest, 40&#x000a0;to 50% of cases), neurofibromatosis type 1 (NF1), and Von Hippel-Lindau syndrome.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref><xref ref-type="bibr" rid="article-71557.r6">[6]</xref>&#x000a0;Moreover, a variety of chromosomal aberrations, including&#x000a0;loss of heterozygosity at chromosome 11q, 6q, and allelic loss at chromosome 3p, are implicated in the pathogenesis of this disease.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref></p>
      </sec>
      <sec id="article-71557.s4" sec-type="Epidemiology">
        <title>Epidemiology</title>
        <p>Somatostatinoma&#x000a0;commonly presents in late adulthood between 40 and 60 years of age&#x000a0;with no gender predilection.<xref ref-type="bibr" rid="article-71557.r7">[7]</xref><xref ref-type="bibr" rid="article-71557.r5">[5]</xref></p>
      </sec>
      <sec id="article-71557.s5" sec-type="Pathophysiology">
        <title>Pathophysiology</title>
        <p>Somatostatinoma can be functional or non-functional. Non-functional tumors are common in the duodenum&#x000a0;and are identified incidentally or from mechanical obstruction of the biliary tree.<xref ref-type="bibr" rid="article-71557.r8">[8]</xref><xref ref-type="bibr" rid="article-71557.r9">[9]</xref><xref ref-type="bibr" rid="article-71557.r1">[1]</xref>&#x000a0;Functional or secretory tumors are common in the pancreas&#x000a0;and are diagnosed with the clinical effects of somatostatin.<xref ref-type="bibr" rid="article-71557.r9">[9]</xref> Somatostatin exerts an inhibitory effect on pituitary hormones such as growth hormone and thyroid-stimulating hormone.<xref ref-type="bibr" rid="article-71557.r5">[5]</xref>&#x000a0;In the neuro gastrointestinal system, somatostatin suppresses the release of&#x000a0;glucagon, pancreatic polypeptide, cholecystokinin, gastrin, secretin, cholecystokinin, vasoactive intestinal polypeptide, gastric inhibitory polypeptide, motilin, glucagon, and neurotensin.<xref ref-type="bibr" rid="article-71557.r5">[5]</xref> It has a direct inhibitory effect on gastric acid secretion, splanchnic perfusion, gastric emptying, gallbladder contractility, bile flow, and bowel motility.<xref ref-type="bibr" rid="article-71557.r5">[5]</xref><xref ref-type="bibr" rid="article-71557.r10">[10]</xref>&#x000a0;</p>
      </sec>
      <sec id="article-71557.s6" sec-type="Histopathology">
        <title>Histopathology</title>
        <p>Pancreatic tumors are generally larger and more malignant than their duodenal counterparts.<xref ref-type="bibr" rid="article-71557.r11">[11]</xref>&#x000a0;Under light microscopy, most tumors show well-differentiated islet cell or carcinoid tumor morphology, while some show a mixed pattern of differentiated and anaplastic cells.<xref ref-type="bibr" rid="article-71557.r7">[7]</xref>&#x000a0;Psammoma bodies are&#x000a0;concentric lamellated calcified structures commonly visualized in duodenal tumors more than the pancreatic tumors.<xref ref-type="bibr" rid="article-71557.r12">[12]</xref>&#x000a0;Neurosecretory granules are visible in the cytoplasm surrounding the Golgi complex and endoplasmic reticulum under electron microscopy<xref ref-type="bibr" rid="article-71557.r4">[4]</xref>, and immunohistochemistry is typically positive for somatostatin and non-specific neuroendocrine markers such as synaptophysin, neuron-specific enolase, chromogranin, and serotonin.<xref ref-type="bibr" rid="article-71557.r1">[1]</xref><xref ref-type="bibr" rid="article-71557.r7">[7]</xref>&#x000a0;In one-fourth of the cases, the tumor is positive for other pancreatic hormones such as insulin, calcitonin, gastrin, glucagon, and vasoactive intestinal polypeptide.<xref ref-type="bibr" rid="article-71557.r6">[6]</xref>&#x000a0;Immunohistochemistry for Ki-67 (MIB-1) is mandatory to grade the tumor based on WHO classification.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref> WHO has classified gastro-entero-pancreatic tumors into grade 1 &#x02013; Ki-67 less than or equal to 2%, grade 2 &#x02013; Ki-67 3%&#x000a0;to 20%, grade 3 &#x02013; Ki-67 over 20%, mixed adenocarcinoma, and neuroendocrine carcinoma.<xref ref-type="bibr" rid="article-71557.r14">[14]</xref></p>
      </sec>
      <sec id="article-71557.s7" sec-type="History and Physical">
        <title>History and Physical</title>
        <p>Non-functional tumors are frequently asymptomatic. Later in the course of the disease, they may present with abdominal pain, vomiting, jaundice, and steatorrhea due to the mechanical effects of the tumor on the biliary and pancreatic drainage.<xref ref-type="bibr" rid="article-71557.r11">[11]</xref>&#x000a0;Functional tumors present with the inhibitory effects of somatostatin on the neuroendocrine system. Cholelithiasis is present in almost 70%, and diabetes mellitus in 60% of symptomatic cases.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref>&#x000a0;Rarely, they manifest as a triad of diabetes mellitus, cholelithiasis, and steatorrhea, referred to as inhibitory syndrome due to the suppression of insulin, cholecystokinin, and pancreatic exocrine enzymes, respectively.<xref ref-type="bibr" rid="article-71557.r5">[5]</xref><xref ref-type="bibr" rid="article-71557.r6">[6]</xref>&#x000a0;The physical examination might reveal icterus in the patients presenting with obstructive jaundice, abdominal tenderness in acute cholecystitis, and neurocutaneous markers&#x000a0;such as cafe au lait spots, neurofibromas, and axillary freckling in patients with concomitant NF1.</p>
      </sec>
      <sec id="article-71557.s8" sec-type="Evaluation">
        <title>Evaluation</title>
        <p>Early diagnosis of somatostatinoma can be difficult as non-functional tumors often produce no symptoms, and functional tumors present with non-specific symptoms that can masquerade other clinical conditions. Hence most non-functional tumors are discovered incidentally or during the workup of vague gastrointestinal symptoms.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref>&#x000a0;Functional tumors typically have elevated fasting serum somatostatin levels (greater than 14 mmol/l).<xref ref-type="bibr" rid="article-71557.r4">[4]</xref>&#x000a0;However, it is important to recognize that serum somatostatin levels may also increase in medullary thyroid cancer, lung cancer, pheochromocytoma, and paraganglioma.<xref ref-type="bibr" rid="article-71557.r15">[15]</xref>&#x000a0;24-hour urine level of 5-hydroxy indole acetic acid (5-HIAA), the breakdown product of serotonin, has been used as an alternative in some centers, but the level can be affected by a variety of dietary items and drugs.<xref ref-type="bibr" rid="article-71557.r16">[16]</xref></p>
        <p>Since somatostatinoma usually presents late, tumors are large at diagnosis and are easily visualized using imaging modalities such as CT, MRI, or MRCP.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref> Multiphasic contrast-enhanced CT abdomen is the initial investigation of choice&#x000a0;due to the non-invasiveness and the widespread availability.<xref ref-type="bibr" rid="article-71557.r17">[17]</xref> MRI is increasingly in use where pNETs have a low signal density on T1-weighted images and high signal density on T2 weighted images.<xref ref-type="bibr" rid="article-71557.r18">[18]</xref> MRI also has a higher sensitivity than CT to detect small liver metastases.<xref ref-type="bibr" rid="article-71557.r17">[17]</xref>&#x000a0;Procedures such as esophagogastroduodenoscopy (EGD), endoscopic retrograde cholangiopancreatography (ERCP), or endoscopic ultrasound (EUS) can be performed to allow luminal visualization and biopsy of the tumor to confirm the diagnosis. EUS offers high sensitivity to detect lesions as small as 0.5 cm and is best indicated for lesions in the head of the pancreas&#x000a0;and lesions of the duodenal wall.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref><xref ref-type="bibr" rid="article-71557.r17">[17]</xref></p>
      </sec>
      <sec id="article-71557.s9" sec-type="Treatment / Management">
        <title>Treatment / Management</title>
        <p>Treatment depends upon the functionality, operability, and staging of the tumor. Surgery with the excision of the primary tumor and all the metastasized lymph nodes is the only curative treatment.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref>&#x000a0;Tumors, where nearly 90% are excisable, are treated with curative resection only.<xref ref-type="bibr" rid="article-71557.r20">[20]</xref>&#x000a0;Tumors with local and locoregional (liver and lymph node) metastases receive treatment with tumor debulking surgeries&#x000a0;and hepatic resection to relieve symptoms secondary to mechanical obstruction and heavy tumor load.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref><xref ref-type="bibr" rid="article-71557.r20">[20]</xref>&#x000a0;Depending on the location of the primary tumor, pylorus-preserving proximal pancreaticoduodenectomy, distal pancreatectomy with splenectomy, and Whipple&#x02019;s procedure are some of the frequently performed procedures.<xref ref-type="bibr" rid="article-71557.r1">[1]</xref><xref ref-type="bibr" rid="article-71557.r3">[3]</xref><xref ref-type="bibr" rid="article-71557.r21">[21]</xref>&#x000a0;Grade 3 pNETs are often widely metastasized at diagnosis, thus are generally rendered inoperable.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref>&#x000a0;</p>
        <p>Isolated liver metastasis should have treatment with resection or selective hepatic transcatheter arterial embolization (TAE).<xref ref-type="bibr" rid="article-71557.r17">[17]</xref> Prospective trials have shown that long-term survival significantly increases with early and aggressive surgical resection of hepatic metastases.<xref ref-type="bibr" rid="article-71557.r22">[22]</xref> In cases of partially resectable multicentric disease or inoperable liver metastases, ablative procedures such as radiofrequency ablation (RFA), laser-induced thermotherapy, &#x000a0;TAE, transcatheter arterial chemoembolization (TACE), and selective internal radiotherapy (SIRT) are employed in addition to systemic chemotherapy to downstage the tumor.<xref ref-type="bibr" rid="article-71557.r23">[23]</xref></p>
      </sec>
      <sec id="article-71557.s10" sec-type="Differential Diagnosis">
        <title>Differential Diagnosis</title>
        <p>Symptoms related to the obstruction of the biliary tree require differentiation from other extrahepatic causes of cholestasis such as choledocholithiasis, choledochal cyst, sclerosing cholangitis,&#x000a0;cholangiocarcinoma,&#x000a0;pancreatic pseudocysts, and pancreatic adenocarcinoma. Similarly, symptoms secondary to pancreatic insufficiencies such as steatorrhea and insulin-dependent diabetes mellitus should raise suspicion of somatostatinoma in addition to chronic pancreatitis and other pancreatic tumors.&#x000a0;</p>
      </sec>
      <sec id="article-71557.s11" sec-type="Medical Oncology">
        <title>Medical Oncology</title>
        <p>Somatostatin analogs such as octreotide and lanreotide are indicated in functional tumors of any size.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref><xref ref-type="bibr" rid="article-71557.r24">[24]</xref><xref ref-type="bibr" rid="article-71557.r25">[25]</xref> They are also recommended as first-line therapy in nonfunctioning grade 1/2 NETs.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref>&#x000a0;Prospective randomized phase III studies have shown that targeted therapy such as tyrosine kinase inhibitor sunitinib malate&#x000a0;and mTOR inhibitor everolimus&#x000a0;lengthen the time to tumor progression compared to placebo in advanced, low-grade, and intermediate-grade pNET, respectively.<xref ref-type="bibr" rid="article-71557.r26">[26]</xref><xref ref-type="bibr" rid="article-71557.r27">[27]</xref><xref ref-type="bibr" rid="article-71557.r26">[26]</xref></p>
        <p>Chemotherapy is recommended in metastatic grade 2 and any grade 3 tumors. Streptozocin with 5&#x02013;fluorouracil or doxorubicin is recommended in grade 2 NETs.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref> A multicenter prospective study has shown Streptozocin and doxorubicin to be more effective than Streptozocin and 5-fluorouracil in advanced pNETs.<xref ref-type="bibr" rid="article-71557.r28">[28]</xref> Temozolomide and capecitabine were found to be effective in metastatic, well, or moderately differentiated pancreatic endocrine carcinoma in a retrospective uncontrolled study&#x000a0;but the comparative effect with streptozocin combinations remains unknown as yet.<xref ref-type="bibr" rid="article-71557.r29">[29]</xref> Similarly, dacarbazine has demonstrated clinical response in one-third of the patients with advanced pNET in a phase II uncontrolled trial.<xref ref-type="bibr" rid="article-71557.r30">[30]</xref> Platinum-based agents combined with etoposide or irinotecan have proven efficacy in poorly differentiated grade 3 tumors and not well-differentiated tumors in a phase II trial.<xref ref-type="bibr" rid="article-71557.r13">[13]</xref><xref ref-type="bibr" rid="article-71557.r31">[31]</xref></p>
      </sec>
      <sec id="article-71557.s12" sec-type="Staging">
        <title>Staging</title>
        <p>Around 75% of the tumors are metastatic at presentation, with liver involvement early in the course of the disease.<xref ref-type="bibr" rid="article-71557.r4">[4]</xref>&#x000a0;There are reports of distant metastasis involving the liver.<xref ref-type="bibr" rid="article-71557.r12">[12]</xref> Staging occurs through&#x000a0;functional imaging tests such as somatostatin receptor scintigraphy (octreotide scan) and positron emission tomography (PET).<xref ref-type="bibr" rid="article-71557.r13">[13]</xref>&#x000a0;Gallium-68 DOTATATE PET has a sensitivity of 94.5% and specificity of 97% for pNETs. They are particularly sensitive to detect bony metastasis compared to octreotide scans (95% vs. 15%, p&#x000a0; &#x0003c; 0.001).<xref ref-type="bibr" rid="article-71557.r32">[32]</xref>&#x000a0;As per the American Joint Committee of Cancer (AJCC), pNETs classified into four stages: stage 1 &#x02013; tumor limited to pancreas, stage 2 &#x02013; tumor extends beyond pancreas not involving superior mesenteric artery or regional lymph node metastasis, stage 3 &#x02013; involvement of the celiac axis or superior mesenteric artery, stage 4 &#x02013; distant metastasis.<xref ref-type="bibr" rid="article-71557.r33">[33]</xref>&#x000a0;Endocrine tumors of the foregut classify into the following: stage 1 &#x02013; size less than or equal to 1&#x000a0;cm with invasion of lamina propria or submucosa; stage 2 &#x02013; tumors size &#x0003e; 1 cm or invades muscularis propria, pancreas, or retroperitoneum; stage 3 &#x02013; metastasis of regional lymph node, peritoneum or adjacent structures; stage 4 &#x02013; distant metastasis.<xref ref-type="bibr" rid="article-71557.r34">[34]</xref></p>
      </sec>
      <sec id="article-71557.s13" sec-type="Prognosis">
        <title>Prognosis</title>
        <p>The 5-year survival rate of patients with pancreatic or periampullary somatostatinoma is 60 to 100% with localized disease and 15 to 60% with metastatic disease.<xref ref-type="bibr" rid="article-71557.r1">[1]</xref>&#x000a0;Prognosis depends on the size of the tumor, the degree of cytological differentiation, the amount of residual tumor post-resection, and the extent of metastasis.<xref ref-type="bibr" rid="article-71557.r35">[35]</xref><xref ref-type="bibr" rid="article-71557.r36">[36]</xref>&#x000a0;In patients who underwent resection, the 5-year survival rates for stages I, II, III, and IV were 89.9%, 82.6%, 75.8%, and 56.9%, respectively.<xref ref-type="bibr" rid="article-71557.r37">[37]</xref>&#x000a0;In a retrospective study on patients with liver metastases, the presence of bone metastasis significantly decreased the median survival (15.4&#x02013;62.1 vs. 18.2&#x02013;166.3 months, p &#x0003c; 0.0001).<xref ref-type="bibr" rid="article-71557.r38">[38]</xref></p>
      </sec>
      <sec id="article-71557.s14" sec-type="Complications">
        <title>Complications</title>
        <p>Systemic complications include diabetes mellitus, cholelithiasis, iron deficiency anemia, macrocytic anemia, deficiency manifestations of fat-soluble vitamins A, D, E, and K such as night blindness, osteopenia, and bleeding, respectively. Diabetes mellitus is usually mild, and ketoacidosis is rare. It is treated with diet and/or oral hypoglycemic agents or with small doses of insulin.<xref ref-type="bibr" rid="article-71557.r7">[7]</xref>&#x000a0;Even if patients do not present with cholelithiasis, prophylactic cholecystectomy is often performed during the initial surgical exploration due to the high prevalence of cholelithiasis among these patients, especially if somatostatin analogs are indicated for treatment.<xref ref-type="bibr" rid="article-71557.r24">[24]</xref>&#x000a0;</p>
        <p>Locally, the tumor can lead to obstructive hyperbilirubinemia and gastrointestinal bleeding.&#x000a0;</p>
      </sec>
      <sec id="article-71557.s15" sec-type="Postoperative and Rehabilitation Care">
        <title>Postoperative and Rehabilitation Care</title>
        <p>Follow-up is recommended for a minimum of 10 years.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref> For fully resected, well-differentiated, or moderately differentiated stage I &#x02013; III gastroenteropancreatic NETs, consensus recommendation from international multidisciplinary working group exists to guide surveillance using cross-sectional imaging and biomarker testing.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref> Follow-up with cross-sectional imaging (triple-phase CT of the abdomen) or MRI is recommended for pancreatic and midgut NET annually for the first three years, then every 1 to 2 years.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref> More frequent surveillance is recommended for the Ki-67 mitotic index greater than 10% or lymph node positivity.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref> Follow-up is not routinely recommended for pancreatic tumors with stage I or grade 1 tumors and midgut NETS, which are incidental TNM stage 1 or grade 1.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref> Biomarkers are not routinely recommended for surveillance.<xref ref-type="bibr" rid="article-71557.r19">[19]</xref>&#x000a0; European Neuroendocrine Tumor Society (ENETS) recommends functional imaging tests at baseline and every 2 years in grade 1, at 3 months, and yearly for grade 2&#x000a0;to 3 pNETs.<xref ref-type="bibr" rid="article-71557.r39">[39]</xref></p>
      </sec>
      <sec id="article-71557.s16" sec-type="Deterrence and Patient Education">
        <title>Deterrence and Patient Education</title>
        <p>Provider awareness and patient education are necessary for prompt diagnosis of the disease and early initiation of treatment. Reliable online resources such as the American Cancer Society can provide evidence-based information to providers and patients.</p>
      </sec>
      <sec id="article-71557.s17" sec-type="Pearls and Other Issues">
        <title>Pearls and Other Issues</title>
        <p>The rarity of the tumor and the wide variation in the non-specific symptomatology requires a high index of suspicion for initial diagnosis. Early diagnosis is imperative as a significant majority of these tumors are metastatic at presentation.&#x000a0;</p>
      </sec>
      <sec id="article-71557.s18" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Advanced cases of somatostatinoma with hepatic metastases often require an interprofessional approach inclusive of a gastroenterologist, surgeon, and oncologist to evaluate the prognosis and treatment choices between curative procedures and palliative therapy. Pharmacologists review treatment with somatostatin analogs or chemotherapy. Specialty-trained nurses assist with surgery, monitor patients preoperatively, and administer treatment.<xref ref-type="bibr" rid="article-71557.r40">[40]</xref>&#x000a0;&#x000a0;[Level 5]</p>
      </sec>
      <sec id="article-71557.s19">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=71557&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=71557">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://mdsearchlight.com/cancer/somatostatinoma/?utm_source=pubmedlink&#x00026;utm_campaign=MDS&#x00026;utm_content=71557">Click here for a simplified version.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/71557/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=71557">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <floats-group id="article-71557.s20">
        <fig id="article-71557.image.f1" position="float" orientation="portrait">
          <caption>
            <p>Somatostatinoma Image courtesy O.Chaigasame</p>
          </caption>
          <graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="somatostatinoma" position="float" orientation="portrait"/>
        </fig>
      </floats-group>
      <ref-list id="article-71557.s21">
        <title>References</title>
        <ref id="article-71557.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Williamson</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Thorn</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Spalding</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Williamson</surname>
                <given-names>RC</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic and peripancreatic somatostatinomas.</article-title>
            <source>Ann R Coll Surg Engl</source>
            <year>2011</year>
            <month>Jul</month>
            <volume>93</volume>
            <issue>5</issue>
            <fpage>356</fpage>
            <page-range>356-60</page-range>
            <pub-id pub-id-type="pmid">21943457</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>de Wilde</surname>
                <given-names>RF</given-names>
              </name>
              <name>
                <surname>Edil</surname>
                <given-names>BH</given-names>
              </name>
              <name>
                <surname>Hruban</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Maitra</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Well-differentiated pancreatic neuroendocrine tumors: from genetics to therapy.</article-title>
            <source>Nat Rev Gastroenterol Hepatol</source>
            <year>2012</year>
            <month>Feb</month>
            <day>07</day>
            <volume>9</volume>
            <issue>4</issue>
            <fpage>199</fpage>
            <page-range>199-208</page-range>
            <pub-id pub-id-type="pmid">22310917</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ganda</surname>
                <given-names>OP</given-names>
              </name>
              <name>
                <surname>Weir</surname>
                <given-names>GC</given-names>
              </name>
              <name>
                <surname>Soeldner</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Legg</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Chick</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Patel</surname>
                <given-names>YC</given-names>
              </name>
              <name>
                <surname>Ebeid</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Gabbay</surname>
                <given-names>KH</given-names>
              </name>
              <name>
                <surname>Reichlin</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>"Somatostatinoma": a somatostatin-containing tumor of the endocrine pancreas.</article-title>
            <source>N Engl J Med</source>
            <year>1977</year>
            <month>Apr</month>
            <day>28</day>
            <volume>296</volume>
            <issue>17</issue>
            <fpage>963</fpage>
            <page-range>963-7</page-range>
            <pub-id pub-id-type="pmid">321960</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mansour</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic endocrine tumors.</article-title>
            <source>J Surg Res</source>
            <year>2004</year>
            <month>Jul</month>
            <volume>120</volume>
            <issue>1</issue>
            <fpage>139</fpage>
            <page-range>139-61</page-range>
            <pub-id pub-id-type="pmid">15172200</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mozell</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Stenzel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Woltering</surname>
                <given-names>EA</given-names>
              </name>
              <name>
                <surname>R&#x000f6;sch</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>O'Dorisio</surname>
                <given-names>TM</given-names>
              </name>
            </person-group>
            <article-title>Functional endocrine tumors of the pancreas: clinical presentation, diagnosis, and treatment.</article-title>
            <source>Curr Probl Surg</source>
            <year>1990</year>
            <month>Jun</month>
            <volume>27</volume>
            <issue>6</issue>
            <fpage>301</fpage>
            <page-range>301-86</page-range>
            <pub-id pub-id-type="pmid">1973365</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Nesi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Marcucci</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Rubio</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Brandi</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Tonelli</surname>
                <given-names>F</given-names>
              </name>
            </person-group>
            <article-title>Somatostatinoma: clinico-pathological features of three cases and literature reviewed.</article-title>
            <source>J Gastroenterol Hepatol</source>
            <year>2008</year>
            <month>Apr</month>
            <volume>23</volume>
            <issue>4</issue>
            <fpage>521</fpage>
            <page-range>521-6</page-range>
            <pub-id pub-id-type="pmid">17645474</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Vinik</surname>
                <given-names>AI</given-names>
              </name>
              <name>
                <surname>Strodel</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Eckhauser</surname>
                <given-names>FE</given-names>
              </name>
              <name>
                <surname>Moattari</surname>
                <given-names>AR</given-names>
              </name>
              <name>
                <surname>Lloyd</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Somatostatinomas, PPomas, neurotensinomas.</article-title>
            <source>Semin Oncol</source>
            <year>1987</year>
            <month>Sep</month>
            <volume>14</volume>
            <issue>3</issue>
            <fpage>263</fpage>
            <page-range>263-81</page-range>
            <pub-id pub-id-type="pmid">2820062</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Brien</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Chejfec</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Prinz</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Clinical features of duodenal somatostatinomas.</article-title>
            <source>Surgery</source>
            <year>1993</year>
            <month>Dec</month>
            <volume>114</volume>
            <issue>6</issue>
            <fpage>1144</fpage>
            <page-range>1144-7</page-range>
            <pub-id pub-id-type="pmid">8256221</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Soga</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yakuwa</surname>
                <given-names>Y</given-names>
              </name>
            </person-group>
            <article-title>Somatostatinoma/inhibitory syndrome: a statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas.</article-title>
            <source>J Exp Clin Cancer Res</source>
            <year>1999</year>
            <month>Mar</month>
            <volume>18</volume>
            <issue>1</issue>
            <fpage>13</fpage>
            <page-range>13-22</page-range>
            <pub-id pub-id-type="pmid">10374671</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Barnett</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Somatostatin and somatostatin receptor physiology.</article-title>
            <source>Endocrine</source>
            <year>2003</year>
            <month>Apr</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-64</page-range>
            <pub-id pub-id-type="pmid">12721505</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tanaka</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Yamasaki</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Matsushita</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Ozawa</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Kurosaki</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Takeuchi</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Hoshihara</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Doi</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Watanabe</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kawaminami</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Duodenal somatostatinoma: a case report and review of 31 cases with special reference to the relationship between tumor size and metastasis.</article-title>
            <source>Pathol Int</source>
            <year>2000</year>
            <month>Feb</month>
            <volume>50</volume>
            <issue>2</issue>
            <fpage>146</fpage>
            <page-range>146-52</page-range>
            <pub-id pub-id-type="pmid">10792774</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hanson</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Howard</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Von Recklinghausen's disease associated with duodenal somatostatinoma: contrast of duodenal versus pancreatic somatostatinomas.</article-title>
            <source>J Surg Oncol</source>
            <year>1995</year>
            <month>May</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>67</fpage>
            <page-range>67-73</page-range>
            <pub-id pub-id-type="pmid">7745981</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Knigge</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Kwekkeboom</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Perren</surname>
                <given-names>A</given-names>
              </name>
              <collab>ESMO Guidelines Working Group</collab>
            </person-group>
            <article-title>Neuroendocrine gastro-entero-pancreatic tumors: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.</article-title>
            <source>Ann Oncol</source>
            <year>2012</year>
            <month>Oct</month>
            <volume>23 Suppl 7</volume>
            <fpage>vii124</fpage>
            <page-range>vii124-30</page-range>
            <pub-id pub-id-type="pmid">22997445</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kl&#x000f6;ppel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>Classification and pathology of gastroenteropancreatic neuroendocrine neoplasms.</article-title>
            <source>Endocr Relat Cancer</source>
            <year>2011</year>
            <month>Oct</month>
            <volume>18 Suppl 1</volume>
            <fpage>S1</fpage>
            <page-range>S1-16</page-range>
            <pub-id pub-id-type="pmid">22005112</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Igarashi</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic neuroendocrine tumors: clinical features, diagnosis and medical treatment: advances.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2012</year>
            <month>Dec</month>
            <volume>26</volume>
            <issue>6</issue>
            <fpage>737</fpage>
            <page-range>737-53</page-range>
            <pub-id pub-id-type="pmid">23582916</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramage</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Ahmed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ardill</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bax</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Breen</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Corrie</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Davar</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Davies</surname>
                <given-names>AH</given-names>
              </name>
              <name>
                <surname>Lewington</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Meyer</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Newell-Price</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Poston</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Rockall</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Steward</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Thakker</surname>
                <given-names>RV</given-names>
              </name>
              <name>
                <surname>Toubanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Verbeke</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Grossman</surname>
                <given-names>AB</given-names>
              </name>
              <collab>UK and Ireland Neuroendocrine Tumour Society</collab>
            </person-group>
            <article-title>Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs).</article-title>
            <source>Gut</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>61</volume>
            <issue>1</issue>
            <fpage>6</fpage>
            <page-range>6-32</page-range>
            <pub-id pub-id-type="pmid">22052063</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>O'Grady</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Conlon</surname>
                <given-names>KC</given-names>
              </name>
            </person-group>
            <article-title>Pancreatic neuroendocrine tumours.</article-title>
            <source>Eur J Surg Oncol</source>
            <year>2008</year>
            <month>Mar</month>
            <volume>34</volume>
            <issue>3</issue>
            <fpage>324</fpage>
            <page-range>324-32</page-range>
            <pub-id pub-id-type="pmid">17967523</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tjon A Tham</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Jansen</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Falke</surname>
                <given-names>TH</given-names>
              </name>
              <name>
                <surname>Lamers</surname>
                <given-names>CB</given-names>
              </name>
            </person-group>
            <article-title>Imaging features of somatostatinoma: MR, CT, US, and angiography.</article-title>
            <source>J Comput Assist Tomogr</source>
            <year>1994</year>
            <season>May-Jun</season>
            <volume>18</volume>
            <issue>3</issue>
            <fpage>427</fpage>
            <page-range>427-31</page-range>
            <pub-id pub-id-type="pmid">8188911</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Singh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Moody</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Asmis</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bailey</surname>
                <given-names>DL</given-names>
              </name>
              <name>
                <surname>Bergsland</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Brendtro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Carroll</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Cleary</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kong</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Law</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lawrence</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>McEwan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>McGregor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Michael</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Pasieka</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Pavlakis</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Pommier</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Soulen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wyld</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Segelov</surname>
                <given-names>E</given-names>
              </name>
              <collab>Commonwealth Neuroendocrine Tumour Collaboration (CommNETS) Follow-up Working Group</collab>
            </person-group>
            <article-title>Follow-up Recommendations for Completely Resected Gastroenteropancreatic Neuroendocrine Tumors.</article-title>
            <source>JAMA Oncol</source>
            <year>2018</year>
            <month>Nov</month>
            <day>01</day>
            <volume>4</volume>
            <issue>11</issue>
            <fpage>1597</fpage>
            <page-range>1597-1604</page-range>
            <pub-id pub-id-type="pmid">30054622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kunz</surname>
                <given-names>PL</given-names>
              </name>
              <name>
                <surname>Reidy-Lagunes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Anthony</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Bertino</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Brendtro</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Chan</surname>
                <given-names>JA</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Jensen</surname>
                <given-names>RT</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>MK</given-names>
              </name>
              <name>
                <surname>Klimstra</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Kulke</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>EH</given-names>
              </name>
              <name>
                <surname>Metz</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Phan</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Sippel</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <collab>North American Neuroendocrine Tumor Society</collab>
            </person-group>
            <article-title>Consensus guidelines for the management and treatment of neuroendocrine tumors.</article-title>
            <source>Pancreas</source>
            <year>2013</year>
            <month>May</month>
            <volume>42</volume>
            <issue>4</issue>
            <fpage>557</fpage>
            <page-range>557-77</page-range>
            <pub-id pub-id-type="pmid">23591432</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zakaria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hammad</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Vakhariya</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Raphael</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Somatostatinoma Presented as Double-Duct Sign.</article-title>
            <source>Case Rep Gastrointest Med</source>
            <year>2019</year>
            <volume>2019</volume>
            <fpage>9506405</fpage>
            <pub-id pub-id-type="pmid">31210994</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r22">
          <label>22</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Glazer</surname>
                <given-names>ES</given-names>
              </name>
              <name>
                <surname>Tseng</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Al-Refaie</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Solorzano</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Willborn</surname>
                <given-names>KA</given-names>
              </name>
              <name>
                <surname>Abdalla</surname>
                <given-names>EK</given-names>
              </name>
              <name>
                <surname>Vauthey</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Curley</surname>
                <given-names>SA</given-names>
              </name>
            </person-group>
            <article-title>Long-term survival after surgical management of neuroendocrine hepatic metastases.</article-title>
            <source>HPB (Oxford)</source>
            <year>2010</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>427</fpage>
            <page-range>427-33</page-range>
            <pub-id pub-id-type="pmid">20662794</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r23">
          <label>23</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Berber</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Flesher</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Siperstein</surname>
                <given-names>AE</given-names>
              </name>
            </person-group>
            <article-title>Laparoscopic radiofrequency ablation of neuroendocrine liver metastases.</article-title>
            <source>World J Surg</source>
            <year>2002</year>
            <month>Aug</month>
            <volume>26</volume>
            <issue>8</issue>
            <fpage>985</fpage>
            <page-range>985-90</page-range>
            <pub-id pub-id-type="pmid">12016479</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r24">
          <label>24</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Anene</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Thompson</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>Saigh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Badakhsh</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ecklund</surname>
                <given-names>RE</given-names>
              </name>
            </person-group>
            <article-title>Somatostatinoma: atypical presentation of a rare pancreatic tumor.</article-title>
            <source>Am J Gastroenterol</source>
            <year>1995</year>
            <month>May</month>
            <volume>90</volume>
            <issue>5</issue>
            <fpage>819</fpage>
            <page-range>819-21</page-range>
            <pub-id pub-id-type="pmid">7733095</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r25">
          <label>25</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Doherty</surname>
                <given-names>GM</given-names>
              </name>
            </person-group>
            <article-title>Rare endocrine tumours of the GI tract.</article-title>
            <source>Best Pract Res Clin Gastroenterol</source>
            <year>2005</year>
            <month>Oct</month>
            <volume>19</volume>
            <issue>5</issue>
            <fpage>807</fpage>
            <page-range>807-17</page-range>
            <pub-id pub-id-type="pmid">16253902</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r26">
          <label>26</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Raymond</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Dahan</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Raoul</surname>
                <given-names>JL</given-names>
              </name>
              <name>
                <surname>Bang</surname>
                <given-names>YJ</given-names>
              </name>
              <name>
                <surname>Borbath</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Lombard-Bohas</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Valle</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Metrakos</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Smith</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vinik</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>JS</given-names>
              </name>
              <name>
                <surname>H&#x000f6;rsch</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Hammel</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Wiedenmann</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Patyna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Lu</surname>
                <given-names>DR</given-names>
              </name>
              <name>
                <surname>Blanckmeister</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Chao</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>364</volume>
            <issue>6</issue>
            <fpage>501</fpage>
            <page-range>501-13</page-range>
            <pub-id pub-id-type="pmid">21306237</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r27">
          <label>27</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Yao</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shah</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Ito</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Bohas</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Wolin</surname>
                <given-names>EM</given-names>
              </name>
              <name>
                <surname>Van Cutsem</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Hobday</surname>
                <given-names>TJ</given-names>
              </name>
              <name>
                <surname>Okusaka</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>de Vries</surname>
                <given-names>EG</given-names>
              </name>
              <name>
                <surname>Tomassetti</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pavel</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Hoosen</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Haas</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Lincy</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Lebwohl</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>&#x000d6;berg</surname>
                <given-names>K</given-names>
              </name>
              <collab>RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group</collab>
            </person-group>
            <article-title>Everolimus for advanced pancreatic neuroendocrine tumors.</article-title>
            <source>N Engl J Med</source>
            <year>2011</year>
            <month>Feb</month>
            <day>10</day>
            <volume>364</volume>
            <issue>6</issue>
            <fpage>514</fpage>
            <page-range>514-23</page-range>
            <pub-id pub-id-type="pmid">21306238</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r28">
          <label>28</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Moertel</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Lefkopoulo</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lipsitz</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Klaassen</surname>
                <given-names>D</given-names>
              </name>
            </person-group>
            <article-title>Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma.</article-title>
            <source>N Engl J Med</source>
            <year>1992</year>
            <month>Feb</month>
            <day>20</day>
            <volume>326</volume>
            <issue>8</issue>
            <fpage>519</fpage>
            <page-range>519-23</page-range>
            <pub-id pub-id-type="pmid">1310159</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r29">
          <label>29</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Fine</surname>
                <given-names>RL</given-names>
              </name>
              <name>
                <surname>Choi</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nasir</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Coppola</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>DT</given-names>
              </name>
              <name>
                <surname>Helm</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Kvols</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas.</article-title>
            <source>Cancer</source>
            <year>2011</year>
            <month>Jan</month>
            <day>15</day>
            <volume>117</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-75</page-range>
            <pub-id pub-id-type="pmid">20824724</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r30">
          <label>30</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Ramanathan</surname>
                <given-names>RK</given-names>
              </name>
              <name>
                <surname>Cnaan</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Hahn</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Carbone</surname>
                <given-names>PP</given-names>
              </name>
              <name>
                <surname>Haller</surname>
                <given-names>DG</given-names>
              </name>
            </person-group>
            <article-title>Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282.</article-title>
            <source>Ann Oncol</source>
            <year>2001</year>
            <month>Aug</month>
            <volume>12</volume>
            <issue>8</issue>
            <fpage>1139</fpage>
            <page-range>1139-43</page-range>
            <pub-id pub-id-type="pmid">11583197</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r31">
          <label>31</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kulke</surname>
                <given-names>MH</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ryan</surname>
                <given-names>DP</given-names>
              </name>
              <name>
                <surname>Enzinger</surname>
                <given-names>PC</given-names>
              </name>
              <name>
                <surname>Zhu</surname>
                <given-names>AX</given-names>
              </name>
              <name>
                <surname>Clark</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Earle</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Michelini</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Fuchs</surname>
                <given-names>CS</given-names>
              </name>
            </person-group>
            <article-title>A phase II trial of irinotecan and cisplatin in patients with metastatic neuroendocrine tumors.</article-title>
            <source>Dig Dis Sci</source>
            <year>2006</year>
            <month>Jun</month>
            <volume>51</volume>
            <issue>6</issue>
            <fpage>1033</fpage>
            <page-range>1033-8</page-range>
            <pub-id pub-id-type="pmid">16865563</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r32">
          <label>32</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sadowski</surname>
                <given-names>SM</given-names>
              </name>
              <name>
                <surname>Neychev</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Millo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shih</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Nilubol</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Herscovitch</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Pacak</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Marx</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Kebebew</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Prospective Study of 68Ga-DOTATATE Positron Emission Tomography/Computed Tomography for Detecting Gastro-Entero-Pancreatic Neuroendocrine Tumors and Unknown Primary Sites.</article-title>
            <source>J Clin Oncol</source>
            <year>2016</year>
            <month>Feb</month>
            <day>20</day>
            <volume>34</volume>
            <issue>6</issue>
            <fpage>588</fpage>
            <page-range>588-96</page-range>
            <pub-id pub-id-type="pmid">26712231</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r33">
          <label>33</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Luo</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Javed</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Strosberg</surname>
                <given-names>JR</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Soares</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Weiss</surname>
                <given-names>MJ</given-names>
              </name>
              <name>
                <surname>Zheng</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Wolfgang</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Cives</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Wong</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Shao</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Tan</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Li</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ni</surname>
                <given-names>Q</given-names>
              </name>
              <name>
                <surname>Shen</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>He</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Yu</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Modified Staging Classification for Pancreatic Neuroendocrine Tumors on the Basis of the American Joint Committee on Cancer and European Neuroendocrine Tumor Society Systems.</article-title>
            <source>J Clin Oncol</source>
            <year>2017</year>
            <month>Jan</month>
            <day>20</day>
            <volume>35</volume>
            <issue>3</issue>
            <fpage>274</fpage>
            <page-range>274-280</page-range>
            <pub-id pub-id-type="pmid">27646952</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r34">
          <label>34</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rindi</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Kl&#x000f6;ppel</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Alhman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Couvelard</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>de Herder</surname>
                <given-names>WW</given-names>
              </name>
              <name>
                <surname>Erikssson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Falchetti</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Komminoth</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>K&#x000f6;rner</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Lopes</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>McNicol</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Nilsson</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Perren</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scarpa</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Scoazec</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Wiedenmann</surname>
                <given-names>B</given-names>
              </name>
              <collab>all other Frascati Consensus Conference participants</collab>
              <collab>European Neuroendocrine Tumor Society (ENETS)</collab>
            </person-group>
            <article-title>TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system.</article-title>
            <source>Virchows Arch</source>
            <year>2006</year>
            <month>Oct</month>
            <volume>449</volume>
            <issue>4</issue>
            <fpage>395</fpage>
            <page-range>395-401</page-range>
            <pub-id pub-id-type="pmid">16967267</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r35">
          <label>35</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Madeira</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Terris</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Voss</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Denys</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Sauvanet</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Flejou</surname>
                <given-names>JF</given-names>
              </name>
              <name>
                <surname>Vilgrain</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Belghiti</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Bernades</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Prognostic factors in patients with endocrine tumours of the duodenopancreatic area.</article-title>
            <source>Gut</source>
            <year>1998</year>
            <month>Sep</month>
            <volume>43</volume>
            <issue>3</issue>
            <fpage>422</fpage>
            <page-range>422-7</page-range>
            <pub-id pub-id-type="pmid">9863490</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r36">
          <label>36</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>House</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Yeo</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Schulick</surname>
                <given-names>RD</given-names>
              </name>
            </person-group>
            <article-title>Periampullary pancreatic somatostatinoma.</article-title>
            <source>Ann Surg Oncol</source>
            <year>2002</year>
            <month>Nov</month>
            <volume>9</volume>
            <issue>9</issue>
            <fpage>869</fpage>
            <page-range>869-74</page-range>
            <pub-id pub-id-type="pmid">12417508</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r37">
          <label>37</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Li</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Gou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Ye</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Assessment of the American Joint Commission on Cancer 8th Edition Staging System for Patients with Pancreatic Neuroendocrine Tumors: A Surveillance, Epidemiology, and End Results analysis.</article-title>
            <source>Cancer Med</source>
            <year>2018</year>
            <month>Mar</month>
            <volume>7</volume>
            <issue>3</issue>
            <fpage>626</fpage>
            <page-range>626-634</page-range>
            <pub-id pub-id-type="pmid">29380547</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r38">
          <label>38</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Skoura</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Michopoulou</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Mohmaduvesh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Panagiotidis</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Al Harbi</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Almukhailed</surname>
                <given-names>O</given-names>
              </name>
              <name>
                <surname>Kayani</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Syed</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Navalkissoor</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ell</surname>
                <given-names>PJ</given-names>
              </name>
              <name>
                <surname>Caplin</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Bomanji</surname>
                <given-names>J</given-names>
              </name>
            </person-group>
            <article-title>The Impact of 68Ga-DOTATATE PET/CT Imaging on Management of Patients with Neuroendocrine Tumors: Experience from a National Referral Center in the United Kingdom.</article-title>
            <source>J Nucl Med</source>
            <year>2016</year>
            <month>Jan</month>
            <volume>57</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-40</page-range>
            <pub-id pub-id-type="pmid">26471695</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r39">
          <label>39</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Partelli</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Bartsch</surname>
                <given-names>DK</given-names>
              </name>
              <name>
                <surname>Capdevila</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Knigge</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Niederle</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nieveen van Dijkum</surname>
                <given-names>EJM</given-names>
              </name>
              <name>
                <surname>Pape</surname>
                <given-names>UF</given-names>
              </name>
              <name>
                <surname>Pascher</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Ramage</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Reed</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Ruszniewski</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Scoazec</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Toumpanakis</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Kianmanesh</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Falconi</surname>
                <given-names>M</given-names>
              </name>
              <collab>Antibes Consensus Conference participants</collab>
            </person-group>
            <article-title>ENETS Consensus Guidelines for Standard of Care in Neuroendocrine Tumours: Surgery for Small Intestinal and Pancreatic Neuroendocrine Tumours.</article-title>
            <source>Neuroendocrinology</source>
            <year>2017</year>
            <volume>105</volume>
            <issue>3</issue>
            <fpage>255</fpage>
            <page-range>255-265</page-range>
            <pub-id pub-id-type="pmid">28237989</pub-id>
          </element-citation>
        </ref>
        <ref id="article-71557.r40">
          <label>40</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Chamberlain</surname>
                <given-names>RS</given-names>
              </name>
              <name>
                <surname>Canes</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Brown</surname>
                <given-names>KT</given-names>
              </name>
              <name>
                <surname>Saltz</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Jarnagin</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Fong</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Blumgart</surname>
                <given-names>LH</given-names>
              </name>
            </person-group>
            <article-title>Hepatic neuroendocrine metastases: does intervention alter outcomes?</article-title>
            <source>J Am Coll Surg</source>
            <year>2000</year>
            <month>Apr</month>
            <volume>190</volume>
            <issue>4</issue>
            <fpage>432</fpage>
            <page-range>432-45</page-range>
            <pub-id pub-id-type="pmid">10757381</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
